HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads Citeline's coverage of pharmaceutical manufacturing. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to manufacturers and their quality organizations. Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals. He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association. Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other.

Latest From Bowman Cox

The Quality Lowdown: Blast From Past At Sun Mohali, Touch Of Future With IT/OT Integration

Ranbaxy consent decree is invoked again after the FDA’s latest inspection unveils backdating at Sun’s Mohali plant. FDA probes Intas plant’s many deceptions, Ipca stumbles on investigations without start dates and Sure-Biochem must admit missing client’s contamination.

Manufacturing Quality

How The US FDA Is Checking For Adequate Controls Against DEG/EG Ingredient Substitution

Agency has increased its efforts to protect the US market from the diethylene glycol and ethylene glycol adulteration linked to hundreds of deaths in seven countries with testing, remote records requests, inspections, import alerts and more. Manufacturing quality compliance director Francis Godwin stresses importance of testing every container, while sharing tips for simplifying the task.

Ingredients Manufacturing

The Story Behind DuPont’s Unprecedented Excipient Warning Letter And Tips On How To Avoid Another

Insights from the FDA’s Francis Godwin on how the agency came to issue a warning letter to a DuPont excipient plant and how the normally under-the-radar sector can ensure GMP compliance.

Ingredients Quality

Revised US FDA Guidance Calls For Testing More Excipients For DEG And EG

Substantial revision of 2007 DEG guidance comes after hundreds of deaths in seven countries inked to diethylene glycol and ethylene glycol adulteration. All containers and lots of certain additional excipients must be tested, and many others should be.

OTC Drugs Guidance Documents

How The US FDA Is Checking For Adequate Controls Against DEG/EG Ingredient Substitution

Agency has increased its efforts to protect the US market from the diethylene glycol and ethylene glycol adulteration linked to hundreds of deaths in seven countries with testing, remote records requests, inspections, import alerts and more. Manufacturing quality compliance director Francis Godwin stresses importance of testing every container, while sharing tips for simplifying the task.

Ingredients Manufacturing

Revised US FDA Guidance Calls For Testing More Excipients For DEG And EG

Substantial revision of 2007 DEG guidance comes after hundreds of deaths in seven countries that were linked to diethylene glycol and ethylene glycol adulteration. All containers and all lots of certain additional excipients must now be tested, and many others should be.

Ingredients Quality
See All
UsernamePublicRestriction

Register